TABLE 1 Clinical and Pathological Features
MALT Lymphoma | Diffuse large B-cell Lymphoma | Total | |||||
|---|---|---|---|---|---|---|---|
API2-MALT1 Fusion Gene | API2-MALT1 Fusion Gene | ||||||
Positive | Negative | Total | Positive | Negative | Total | ||
Number of cases | 7 | 40 | 47 | 1 | 12 | 13 | 60 |
Mean of age (range) | 58 (54–70) | 65 (37–87) | 65 (37–87) | 45 | 59 (14–85) | 58 (14–85) | 63 (14–87) |
Sex (M/F) | 6/1 | 11/29 | 17/30 | 1/0 | 6/6 | 7/6 | 24/36 |
Site of tumor | |||||||
Cecum | 0 | 5 | 5 | 0 | 3 | 3 | 8 |
Appendix | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
Ascending colon | 0 | 0 | 0 | 0 | 3 | 3 | 3 |
Transverse colon | 1 | 2 | 3 | 1 | 1 | 2 | 5 |
Descending colon | 1 | 0 | 1 | 0 | 0 | 0 | 1 |
Sigmoid colon | 1 | 3 | 4 | 0 | 0 | 0 | 4 |
Rectum | 3 | 24 | 27 | 0 | 2 | 2 | 29 |
Multiple sites | 1 | 6 | 7 | 0 | 2 | 2 | 9 |
Size of tumor (mm) | |||||||
Mean (range) | 62 (18–115) | 25 (5–65) | 31 (5–115) | 30 | 65 (30–160) | 62 (30–160) | 37 (5–160) |
Shape | |||||||
Elevated | 5 | 37 | 42 | 0 | 4 | 4 | 46 |
Ulcerative | 1 | 2 | 3 | 1 | 7 | 8 | 11 |
Other | 1 | 1 | 2 | 0 | 1 | 1 | 3 |
Depth of tumor | |||||||
m | 0 | 2 | 2 | 0 | 0 | 0 | 2 |
sm | 2 | 19 | 21 | 0 | 0 | 0 | 21 |
mp | 0 | 5 | 5 | 0 | 2 | 2 | 7 |
ss | 3 | 6 | 9 | 1 | 4 | 5 | 14 |
Beyond ss | 0 | 5 | 5 | 0 | 3 | 3 | 8 |
Clonality detected by PCR | |||||||
Clonal | 5 | 22 | 27 | 0 | 10 | 10 | 37 |
Not clonal | 0 | 10 | 10 | 0 | 2 | 2 | 12 |
Nuclear staining of BCL10 | |||||||
Positive | 5 | 4 | 9 | 1 | 3 | 4 | 13 |
Negative | 1 | 20 | 21 | 0 | 6 | 6 | 27 |
Clinical stage† | |||||||
I | 0 | 27 | 27 | 0 | 3 | 3 | 30 |
II | 3 | 5 | 8 | 1 | 4 | 5 | 13 |
IV | 4 | 5 | 9 | 0 | 2 | 2 | 11 |
IPI‡ | |||||||
L | 4 | 25 | 29 | 1 | 4 | 5 | 34 |
LI | 2 | 5 | 7 | 0 | 2 | 2 | 9 |
HI | 1 | 1 | 2 | 0 | 1 | 1 | 3 |
H | 0 | 3 | 3 | 0 | 0 | 0 | 3 |
Therapy | |||||||
Surgery (Surg) | 2 | 15 | 17 | 0 | 3 | 3 | 20 |
Endoscopic resection (Endo) | 0 | 9 | 9 | 0 | 0 | 0 | 9 |
Chemotherapy (Chemo) | 0 | 1 | 1 | 0 | 3 | 3 | 4 |
Eradication of H. pylori (Erad) | 1 | 0 | 1 | 0 | 0 | 0 | 1 |
Rituximab | 0 | 1 | 1 | 0 | 0 | 0 | 1 |
Combined therapy | |||||||
Surg + Chemo | 2 | 4 | 6 | 0 | 4 | 4 | 10 |
Surg + Endo | 0 | 1 | 1 | 0 | 0 | 0 | 1 |
Surg + Erad + Chemo | 0 | 1 | 1 | 1 | 0 | 1 | 2 |
Surg + Endo + Chemo | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
Surg + Chemo + Erad + Radiation | 1 | 0 | 1 | 0 | 0 | 0 | 1 |
Endo + Chemo | 0 | 2 | 2 | 0 | 0 | 0 | 2 |
Endo + Erad | 0 | 3 | 3 | 0 | 0 | 0 | 3 |
Endo + Radiation | 0 | 1 | 1 | 0 | 0 | 0 | 1 |
Chemo + Radiation | 0 | 1 | 1 | 0 | 0 | 0 | 1 |
Chemo + Erad + Rituximab | 1 | 0 | 1 | 0 | 0 | 0 | 1 |
Observation | 0 | 1 | 1 | 0 | 0 | 0 | 1 |
Not done | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
Follow-up | |||||||
Mean (range months) | 39 (2–117) | 32 (2–133) | 33 (2–133) | 78 | 27 (1–99) | 31 (1–99) | 32 (1–133) |
Alive | 7 | 36 | 43 | 1 | 7 | 8 | 51 |
Died | 0 | 2 | 2 | 0 | 2 | 2 | 4 |
Lost | 0 | 2 | 2 | 0 | 3 | 3 | 5 |
